Related Experiment Video

Updated: Apr 6, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

8.1K

Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents

Jing Zhao1, Si-Shen Feng2,3

  • 1Department of Biomedical Engineering, Faculty of Engineering, National University of Singapore, Singapore 117576, Singapore.

Nanomedicine (London, England)
|July 28, 2015
PubMed

Insights

Multidrug resistance in cancer is a major challenge. Nanocarriers offer a promising solution for delivering small interfering RNA (siRNA) and enhancing cancer treatment efficacy through co-delivery strategies.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Oncology

Background:

  • Multidrug resistance (MDR) significantly limits the effectiveness of cancer chemotherapy.
  • Small interfering RNA (siRNA) holds therapeutic potential but faces delivery challenges.
  • Co-delivery of siRNA with anticancer agents via nanocarriers may enhance therapeutic outcomes.

Purpose of the Study:

  • To provide a comprehensive review of nanocarriers for siRNA delivery in cancer treatment.
  • To explore the potential of co-delivery systems for enhanced synergistic effects.
  • To summarize the synthesis, design, characterization, and evaluation of various nanocarrier platforms.

Main Methods:

  • Literature review of nanocarrier systems for siRNA delivery.
  • Analysis of synthesis, material design, and characterization techniques.
  • Evaluation of in vitro and in vivo studies on nanocarrier performance.

Main Results:

  • Various nanocarriers, including liposomes, micelles, dendrimers, and polymeric nanoparticles, are effective for siRNA delivery.
  • Co-delivery systems demonstrate potential for additive or synergistic anticancer effects.
  • Challenges in nanocarrier development include efficient synthesis, targeted delivery, and clinical translation.

Conclusions:

  • Nanocarriers are crucial for overcoming siRNA delivery barriers in cancer therapy.
  • Co-delivery strategies using nanocarriers offer a promising approach to combat multidrug resistance.
  • Further research is needed to optimize nanocarrier design and clinical application for improved cancer treatment.
Keywords:
RNAi therapeuticsbiodegradable polymercancer nanotechnologychemotherapymolecular biomaterialsmultidrug resistancenanotheranostics

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.3K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
114
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.7K